Kymera Therapeutics Business Summary

Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical leader pioneering targeted protein degradation (TPD) through its proprietary Pegasus™ platform. The company’s business model centers on the discovery and development of novel small-molecule degraders that eliminate disease-causing proteins previously considered "undruggable." Kymera generates revenue primarily through high-value strategic collaborations and milestone payments from global pharmaceutical partners, including a multi-program immunology alliance with Sanofi, a molecular glue collaboration with Gilead Sciences, and a multi-target partnership with Vertex Pharmaceuticals. Its primary business segments are focused on Immunology and Inflammation—headlined by its first-in-class oral STAT6 degrader (KT-621) and IRAK4 degrader (KT-474/SAR444656)—and Oncology, targeting STAT3 and MDM2. Within the competitive landscape, Kymera competes directly with TPD specialists such as Arvinas, Nurix Therapeutics, and C4 Therapeutics. Kymera distinguishes itself by being the first to transition TPD technology from oncology into large-market inflammatory diseases, positioning it as the frontrunner in oral immunology degraders. The company was co-founded by President and CEO Nello Mainolfi, Ph.D., and Chairman Bruce Booth, D.Phil., of Atlas Venture. Dr. Mainolfi, a former Entrepreneur-in-Residence at Atlas and Novartis lead, has steered the firm from its 2016 inception to a multi-billion dollar valuation. The executive leadership team features deep industry pedigree, including Chief Development Officer Neil Graham, MBBS (formerly of Regeneron and Vertex), Chief Medical Officer Jared Gollob, MD (Alnylam), and Chief Financial Officer Bruce Jacobs, CFA. Kymera’s board of directors includes prominent figures such as Lead Independent Director Felix Baker and former Alnylam CEO John Maraganore. The company is backed by a sophisticated investor base and strategic partners like Sanofi and Vertex, reflecting strong institutional confidence in its ability to scale its E3 ligase-driven discovery engine into a fully integrated, global immunology powerhouse.